ROCKVILLE, Md., March 06, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the
development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary
NAV® Technology Platform, today announced that Kenneth T. Mills, President and Chief Executive Officer, will present at
the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:40 a.m. ET at the Boston
Marriott Copley Place in Boston. In addition, REGENXBIO representatives will be holding one-on-one meetings at the conference.
A live webcast of the presentation can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the webcast
will be available on the same website for approximately 30 days following the presentation.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant
adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary AAV gene delivery
platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s
mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and
commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology
Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and
third-party NAV Technology Platform Licensees. REGENXBIO and its licensees are applying the NAV Technology Platform in
the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 heather@argotpartners.com Media Laura Bagby, 312-448-8098 lbagby@6degreespr.com
